China Jo-Jo Drugstores Files 6-K Report

TL;DR

China Jo-Jo Drugstores (JJDC) filed a 6-K, confirming 20-F annual reports and Hangzhou HQ.

AI Summary

China Jo-Jo Drugstores, Inc. filed a Form 6-K on January 15, 2025, reporting for the month of January 2025. The filing confirms the company is a Cayman Islands exempted company and provides its principal executive office address in Hangzhou City, China. It also indicates that the company files annual reports under Form 20-F.

Why It Matters

This filing serves as an update for investors regarding the company's reporting status and administrative details, confirming its foreign private issuer status and filing schedule.

Risk Assessment

Risk Level: low — This is a routine administrative filing (6-K) that does not contain new financial results or significant operational updates.

Key Numbers

• 001-40724 — SEC File Number (Identifies the company's filing with the SEC.)

Key Players & Entities

• China Jo-Jo Drugstores, Inc. (company) — Registrant
• 001-40724 (company) — Commission File Number
• 20250115 (date) — Filing Date
• January, 2025 (date) — Reporting Period
• Hangzhou City, China (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $7,414,685 — holesale business, revenue decreased by $7,414,685 or 9.4% for the six months ended Septem
• $1,090,267 — ended September 30, 2024, increased by $1,090,267, or 3.0% compared to the six months end
• $37,734,640 — six months ended September 30, 2023 to $37,734,640. However, excluding the impact of excha
• $580,538 — sting stores increased by approximately $580,538, or 1.6%, while new stores contributed
• $509,729 — le new stores contributed approximately $509,729 in revenue in the six months ended Sept
• $1,576,762 — armacy sales decreased by approximately $1,576,762, or 9.9% for the six months ended Septe
• $6,928,190 — future. Wholesale revenue decreased by $6,928,190 or 26.6%. As a local wholesale distribu
• $1,335,657 — Gross Profit Gross profit decreased by $1,335,657 or 8.4% period over period primarily as
• $59,143 — ing and marketing expenses increased by $59,143 or 0.4%, as compared to the same period
• $1,083,912 — nd administrative expenses increased by $1,083,912 or 66.4%, as compared to the same perio
• $0.2 million — 2024, we reversed bad debt allowance of $0.2 million as compared to reversal of bad debt all
• $0.9 million — ed to reversal of bad debt allowance of $0.9 million in the six months ended September 30, 2
• $0.8 million — bt allowance decreased by approximately $0.8 million. Such expenses as a percentage of reven
• $1,642,910 — September 30, 2024 is nil, decreased by $1,642,910, or 100%, as compared to $1,642,910 the
• $2,222,730 — e above, we had loss from operations of $2,222,730 for the six months ended September 30,

Filing Documents

• ea0227360-6k_china.htm (6-K) — 246KB
• 0001213900-25-003642.txt ( ) — 1461KB
• cjjd-20240930.xsd (EX-101.SCH) — 8KB
• cjjd-20240930_cal.xml (EX-101.CAL) — 38KB
• cjjd-20240930_def.xml (EX-101.DEF) — 65KB
• cjjd-20240930_lab.xml (EX-101.LAB) — 155KB
• cjjd-20240930_pre.xml (EX-101.PRE) — 76KB
• ea0227360-6k_china_htm.xml (XML) — 68KB

Financial Statements

Financial Statements 1 Condensed consolidated balance sheets as of September 30, 2024 (Unaudited) and March 31, 2024 1 Unaudited condensed consolidated statements of operations and comprehensive loss for the six months ended September 30, 2024 and 2023 2 Unaudited condensed consolidated statements of changes in shareholders' equity for the six months ended September 30, 2024 and 2023 3 Unaudited condensed consolidated statements of cash flows for the six months ended September 30, 2024 and 2023 4

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 5 i

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS CHINA JO-JO DRUGSTORES, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS September 30, March 31, 2024 2024 (Unaudited) ASSETS CURRENT ASSETS Cash and cash equivalents $ 18,001,171 $ 20,149,806 Restricted cash 13,091,736 12,724,365 Trade receivable 16,920,749 15,824,103 Inventories 18,774,831 16,248,373 Other receivables, net 2,120,851 2,938,049 Advances to suppliers 1,062,427 914,776 Due from related parties 340,981 313,346 Other current assets 768,898 569,544 Total current assets 71,081,644 69,682,362 NON-CURRENT ASSETS Property and equipment, net 5,011,986 4,906,589 Long-term investment 1,229,785 1,195,261 Farmland assets 652,470 634,153 Long-term deposits 1,041,305 1,119,006 Other noncurrent assets 696,720 682,437 Operating lease right-of-use assets 11,420,641 13,827,360 Intangible assets, net 3,056,938 3,009,922 Total non-current assets 23,109,845 25,374,728 Total assets $ 94,191,489 $ 95,057,090 LIABILITIES AND SHAREHOLDERS' EQUITY CURRENT LIABILITIES Short-term loan payable $ 284,998 $ 276,997 Accounts payable 27,241,130 31,630,131 Notes payable 32,689,034 31,676,335 Other payables 1,291,996 2,493,482 Other payables - related parties 1,986,619 1,833,509 Customer deposits 474,677 518,241 Taxes payable 509,234 682,239 Accrued liabilities 399,728 386,395 Current portion of operating lease liabilities 2,659,985 4,862,766 Total current liabilities 67,537,401 74,360,095 Long-term operating lease liabilities 6,532,936 6,403,858 Total liabilities 74,070,337 80,763,953 COMMITMENTS AND CONTINGENCIES SHAREHOLDERS' EQUITY Ordinary shares; $ 0.24 par value; 150,000,000 shares authorized; 6,654,077 and 1,743,362 shares issued and outstanding as of September 30, 2024 and March 31, 2024, respectively 1,596,979 418,407 Preferred shares; $ 0.001 par value; 10,000,000 shares authorized; none issued a

MANAGEMENT'S DISCUSSION AND ANALYSIS OF

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. The following management's discussion and analysis should be read in conjunction with our unaudited condensed consolidated financial statements. In addition to historical information, the following discussion contains certain forward-looking statements within the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements relate to our future plans, objectives, expectations and intentions. These statements may be identified by the use of words such as "may," "will," "could," "expect," "anticipate," "intend," "believe," "estimate," "plan," "predict," and similar terms or terminology, or the negative of such terms or other comparable terminology. Although we believe the expectations expressed in these forward-looking from those discussed in these statements. Factors that could contribute to such differences include, but are not limited to, those discussed in the "Risk Factors" section of our annual report on Form 20-F for the year ended March 31, 2024 and filed with the SEC on July 30, 2024. We undertake no obligation to update publicly any forward-looking statements for any reason even if new information becomes available or other events occur in the future. Our financial statements are prepared in U.S. Dollars and in accordance with accounting principles generally accepted in the United States. See "Exchange Rates" below for information concerning the exchanges rates at which Renminbi ("RMB") were translated into U.S. Dollars ("USD" or "

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: January 15, 2025 CHINA JO-JO DRUGSTORES, INC. By: /s/ Lei Liu Name: Lei Liu Title: Chief Executive Officer 9

View Full Filing

View this 6-K filing on SEC EDGAR